



GUIDELINES

ON RECALL AND RAPID ALERT SYSTEM FOR DRUGS

(Including Biologicals & Vaccines)



GUIDELINES ON RECALL AND RAPID ALERT SYSTEM FOR DRUGS

(Including Biologicals & Vaccines)

VERSION: 2017

Document No : CDSCO/RRAS Ver. : 00
Effective Date : 23/11/2012

CENTRAL DRUGS STANDARD CONTROL ORGANISATION

Directorate General of Health Services, Ministry of Health and Family Welfare
Government of India

FDA Bhawan, ITO, Kotla Road, New Delhi -110002.

CONTENTS

- 1.0 Introduction
- 2.0 Background
- 3.0 Scope
- 4.0 Definitions
- 5.0 Recall Classification
- 6.0 Recall Procedures
 - 6.1 Voluntary Recall
 - 6.2 Statutory Recall
- 7.0 Level of Recall
- 8.0 Time Lines for Effective Recall System & Rapid Alert
- 9.0 Procedure for Rapid Alert & Recall System
- 10.0 Overview of Process Flow Rapid Alert & Recall System
- 11.0 Stepwise Recall Procedure
- 12.0 Follow-up Action of Recalled Goods
- 13.0 Mock Recall
- 14.0 Abbreviations
- 15.0 References

1.0 INTRODUCTION:

Recall is an action taken to withdraw/remove the drugs from distribution or use including corrective action for which deficiencies are reported in quality, efficacy or safety. The defective products related to quality includes Not of Standard Quality, Adulterated or Spurious drugs. Safety and efficacy related recalls include serious adverse reactions and death. Recalls also include drugs prohibited under the Provisions of Drugs & Cosmetics Act and also those products for which product licenses are suspended/cancelled.

Rapid Alert System is to transmit only those alerts whose urgency and seriousness cannot permit any delay in transmission. Assessment must be made of the seriousness of the defect, its potential for causing harm to the patient or harm to animals (in case of veterinary product), consumers, operators and the environment.

2.0 BACKGROUND:

In the Drugs & Cosmetics Act & Rules, there are references for product recalls, complaint and adverse reactions in Para 27 & 28 of Schedule M and also conditions of license for defective product recall in Rule 74(j) and Rule 78(i), but effective and uniform recall procedure, with time lines at every level of supply chain is required and at present auditing and accountability is not in place. This has been observed in instances where drugs declared as not of standard quality by Government Analyst, incidents where serious adverse effects or death have been reported, in case of banned drugs under Section 26 A, defects where in voluntarily the manufacturer withdraws drugs from the market etc.

3.0 SCOPE:

These guidelines is applicable to all quality defective product reports and to all reported incidents of safety and efficacy received for all drugs including vaccines & biological. These guidelines are expected to be followed by licensees (manufacturers, importers, stockists, distributors, retailers) and the recall could be voluntary or statutory. The procedure may also be used by Drugs Control Authorities of Central or State when urgent action is required to protect public or animal health. These guidelines would help in adopting to stepwise procedures to be followed in recall strategy and also help in recall evaluation at every level and achieve compliance within the time frame.

4.0 DEFINITIONS:

RECALL: Removal or correction of marketed products deficiencies in quality, safety or efficacy, including labeling of the laws. for the reasons relating to considered to be in violation

BATCH RECALL: Process for removal of selected batch/es of a product which are found to be defective and pose health risk to the consumers if left in the market.

BATCH (LOT): A specific quantity of material produced in a process or series of processes so that it is expected to be homogeneous within specified limits.

CUSTOMER: Any person, firm or party buying/receiving goods from the company for storage, distribution and sale.

VOLUNTARY RECALL: A recall initiated by the licensee (in case of loan licensee jointly the contract giver and contract acceptor) as a result of abnormal observation in any product quality during periodic review (Internal / External) or investigation of a market complaint or any other failures.

STATUTORY RECALL: A recall directed by Drug Control Authorities after notifying that product is considered to be in violation of the laws. e.g., Declared as Not of Standard Quality by Government Analyst and Banned under 26A of Drugs and Cosmetics Act 1940 (as amended from time to time) and as well as contravention of Rule 104-A of Drugs & Cosmetics Rules 1945 (as amended from time to time)

5.0 RECALL CLASSIFICATION:

Recall classification is a numerical designation, I, II, or III, that is assigned to a particular product recall that indicates the relative degree of health hazard by country regulatory authorities.

In case of not of standard quality drugs, the recommendations of 39th DCC guidelines for category A,B and C may be accordingly adopted for Class I, Class II and Class III until further recommendations if any. All banned Drugs & Products for which license is suspended, cancelled which are in circulation in market shall also be considered to be Class I recalls only.

CLASS I is a situation in which there is a reasonable probability that the use of, or exposure to, a defective product will cause serious adverse health consequences or death and as well as banned under 26A of Drugs and Cosmetics Act 1940.

CLASS II is situation in which the use of, or exposure to, a defective product may cause temporary adverse health consequences or where the probability of serious adverse health consequences is remote.

CLASS III is a situation in which the use of, or exposure to, a defective product is not likely to cause any adverse health consequences.

6.0 RECALL PROCEDURES:

Any batch of a product not meeting the defined quality standards has to be recalled from the market. Recall can be of two types; Voluntary Recall and Statutory Recall.

6.1 VOLUNTARY RECALL:

Voluntary recall can be triggered by any incident that affects the quality, safety and efficacy of the batch/product in question such as

1. If the batch or batches are found to be not complying with the regulatory specifications during the post marketing stability study

2. If the batch is found to be defective during investigation of market complaint.
3. During any failure investigation, if it is observed that the failure under investigation might have adverse quality impact on already released batch (e.g. possibility of contamination, mix-up, degradation etc).
4. If any unusual observation is noted during visual inspection of retention samples which indicate an impact on quality of the product after investigation.
5. If the post marketing surveillance reports /pharmacovigilance reports indicates that there is serious safety risk associated with the product.

6.2 STATUTORY RECALL:

Statutory recall can be triggered in response to the direction or mandate by the Drug Regulatory Authorities (Central/State) in one or more of the situations as follows :

1. To recall the drug product/batch, considered to be in violation of the laws, it administers such as not of standard quality etc.
2. To recall the banned drugs.
3. Labeling and / or Promotional materials, that are considered to be in violation of law.
4. Product, violation Rule 106 (Diseases under Schedule J)

7.0 LEVELS OF RECALL:

The level (or depth) of recall of a product/batch shall be determined based on recall classification and level to which distribution has taken place.

There are three levels of recall such as consumer/user, retail and wholesale.

CONSUMER OR USER LEVEL: which may vary with product, including any intermediate wholesale or retail level. Consumer or user may include individual consumers, patients, physicians and hospitals.

RETAIL LEVEL: recall to the level immediately preceding consumer or user level. It includes retail groceries, pharmacies, hospital pharmacies, dispensing physician, institutions such as clinics and nursing homes, etc.

WHOLESALE LEVEL: all distribution levels between the manufacturer and retailer.

All Class I recalls shall be executed to the levels of Wholesale/Distributors, retail, and consumer. In such cases, public announcements shall be made using print/electronic media aids viz. Newspapers, Television, Radio etc.

All Class II recalls shall be executed up to the levels of wholesale and retail.

All Class III recalls shall be executed up to the levels of wholesale.

8.0 TIME LINES FOR EFFECTIVE RECALL SYSTEM & RAPID ALERT:

Based on the category of risks involved, a time line of within 24 hours up to a maximum of 72 hours for Class I recall, for class II recall up to a maximum of 10 days and for Class III recall up to a maximum of 30 days is allowed.

The time line for initiation of recall procedure to commence from the receipt of information as notified by the concerned State/ Central Drugs Control Department under statutory recall or voluntary recall by the manufacturer on its own.

The recall has to be initiated immediately without any prejudice of the outcome of Section 25(3) and Section 25(4) of the Drugs & Cosmetics Act 1940 for adducing the evidence. The time line for stopping sale/distribution of defective product under Class I shall be ensured within 24 hours and the physical recall being completed within 72 hours. The Class II and Class III recalls shall be ensured upto 10 and upto 30 days respectively.

9.0 PROCEDURE FOR RAPID ALERT & RECALL SYSTEM:

As soon as the product/batch(es) to be recalled is/are identified, licensee or representative of licensee or QA in charge shall review the information related to the defective product/batch(es) and decide about recall as per the procedure established.

The decision on recall of the defective product/batch shall be made within 24 Hours up to maximum of 72 Hours for Class I recall upon receipt of the intimation.

Within 24 Hours of the decision taken for the recall of the product/batch(es) the communication shall be sent stating the severity of the defect, using the fastest mode of communication which may include email, telephone, fax, SMS etc to the entire supply chain.

The licensee/representative of licensee where the product is marketed shall inform the concerned regulatory authorities where the product batch(es) in question was distributed immediately after the decision of recall has been taken. Further actions on recall will be undertaken according to class of recall.


Recall classification of the product/batch in question shall be done based on the risk assessment in line with the recall classification as given in definition.

It shall be the responsibility of the manufacturer and marketing company to inform up to retail level on the reason of recall in his freeze stock notice.

It shall be the responsibility of distributor/marketing company/ retailer to inform the stock position of product being recalled to his immediate supplier or manufacturer and also his area Drugs Inspector.

The recall notice received, the stock at that time, the procedure for freezing the stock and returned back records shall be maintained by the distributor/retailer and shall be made available for verification by area Drugs Inspector who shall verify and report on its timely freezing and return.

10.0 OVERVIEW OF PROCESS FLOW RAPID ALERT & RECALL SYSTEM: ACTIVITY



* Note: Recall shall be initiated & completed as per timelines of recall classification.

11.0 STEPWISE RECALL PROCEDURE:

The licensee/representative of licensee/Quality Head in charge shall enter the details in the "Recall Log" and assign a unique recall reference number representing the serial number for a particular year in which the recall has been initiated.

The licensee/representative of licensee/ Quality Head in charge shall inform the Distributor/ Marketing Company with fastest mode of communication which may include email, telephone, fax, sms etc. to stop further distribution of the batch(es) in the stock and call back the stock available with the distributors, retailers etc, depending on the seriousness of the defect.

"Product/batch Recall Notice" shall be filled and sent by licensee/representative of licensee/ Quality Head in charge to Distributor / Marketing Company.

Distributor / Marketing Company shall immediately check the distribution record to identify the Customers and Warehouse, depots where the subject product / batches have been distributed and forward the copies of the Recall Notice to them for further necessary action.

The Head of depot(s) shall fill "Recall Notification" and forward it to all distributors to return all unsold stock. Simultaneously, the Heads of respective depots /ware houses shall block the available stock. The Distribution Head shall ensure the blockage of stock for further sale by reviewing the record.

The distributor(s) shall send the "Return Feedback" along with goods (if any) to the depots. All the returned stocks shall be further forwarded to the ware houses.

The Head of ware houses shall send a periodical report to licensee/representative of licensee /QA head of the stock available with them and the returns received from depots.

Head of ware house shall reconcile the stocks of the recalled materials against the total quantity of distributed material and fill the "Summary Report of Product / Batch Recall". The copy shall be forwarded to licensee/representative of licensee/QA in charge for review and necessary action.

The recall of the product/batch shall be completed depending on the class of recall within the stipulated time.

12.0 FOLLOW-UP ACTION OF RECALLED GOODS:

The follow-up action consists of a check on the effectiveness of the recall, an investigation of the reason for the recall and remedial action taken to prevent a recurrence of the defect.

The licensee/representative of licensee/QA Head shall monitor the recall process of product/batch to determine whether the recall is progressing satisfactorily.

The stocks of recalled goods shall be placed under "Quarantine" and stored separately under lock and key in a secure area until further decision.

Wherever required, QA Head of the manufacturing site shall perform the physical inspection of recalled goods and collect sample from recalled goods for investigation to establish the root cause of the product quality defect.

The investigation of the recalled batch(es) shall be conducted as per the SOP of the licensee, on "Investigation of Non-conformities" to identify the root cause of the failure and initiate corrective and preventive actions

Impact assessment shall be conducted on other batches of the concerned product and further extended to batch(es) of other product(s), wherever applicable.

If the cause of recall is established to be quality issue associated with any of the raw material used, then the traceability of that material shall be established in all the product/batches.

Alternatively execute the transaction through records to identify the batches / products in

which the identified material has been used.

Monitoring the relevant data i.e. Material, Plant and Batch Number in respective fields.

Identify the raw material traceability in different formulations and its functions.

List all raw materials along with batch numbers and the respective quantities used in those batches.

List all the products along with batch numbers and the respective quantities used in those batches.

Calculate the total quantity by adding individual quantities used in various products / batches.

Monitoring of the material movement to get the complete overview of stock for that particular material in the plant and extract the information about total quantity received and the balance quantity.

The balance stock, if any shall be verified against the actual physical stock available. QA shall block the remaining available stock.

All material shall be accounted for after the reconciliation

The decision to recall, if necessary, any of the impacted batches shall be made after product quality assessment.

Based on conclusion of the investigation findings, the QA Head / representative of licensee shall direct the Distributor / Marketing Company for appropriate disposition of the batch(es) of the recalled goods as per the regulations.

13.0 MOCK RECALL:

Mock recall shall be carried out for at least one batch of any product, dispatched for sale where maximum distributors are involved, to test the effectiveness of the arrangements of recall. Effectiveness of recall procedure can also be checked by "evaluation of a real recall".

During mock recall traceability shall be performed for at least, one of the raw material used in the batches identified for mock recall.

Mock Recall shall be performed at least once for the longest distribution chain and whenever there is a change in distributor/marketing company.

Records of such mock recall should be maintained by the QA Head of the company.

Abbreviations:

Acronym	Full Form
QA	Quality Assurance
CAPA	Corrective and Preventive Action


References:

1. The Drugs & Cosmetics Act 1940 & Rules 1945.
2. The WHO TRS for GMP Guidelines.
3. Work Shop on Recall & Rapid Alert System, held at New Delhi Office from 27th to 30th August 2012 organized by CDSCO in collaboration with WHO.
4. USFDA documents on recall.
5. The Guidelines on Recall & Rapid Alert System for Drugs including Biologicals and Vaccines.
6. 43rd DCC sub-committee Guidelines.

CENTRAL DRUGS STANDARD CONTROL ORGANIZATION

CENTRAL DRUGS STANDARD CONTROL ORGANIZATION, DGHS

Authorized Personnel Only

	TITLE		Division Name	Quality Assurance	
	Procedure for Recall and Rapid Alert System for Drugs including Biological & Vaccines		Document No.	QA-GNL-021	
			Revision No.	02	
			Effective Date	01.08.2015	
			Page No.	1 of 5	
Prepared By		Approved By		Authorized By	
Name		Name		Name	
Designation		Designation		Designation	
Sign		Sign		Sign	
Date		Date		Date	
					Control Status

1.0 PURPOSE

To lay down uniform procedure and execute the statutory powers as per Drugs & Cosmetics Act and Rules for directing and ensuring rapid alert & effective recall/ destruction of drug products from the market, which are found not of standard quality and / reported of any serious adverse effects/death.

2.0 SCOPE

This document is applicable to all the licensing authority responsible for licensing of manufacture, stock, distribution or sale of drugs and for harmonized implementation within the state as well as for interstate co- ordination.

3.0 RESPONSIBILITY

3.1 The SLA/CLAA (in case of CLAA approved products) shall be responsible for issuing letter /order for stop use at all levels and recall of products which are found not of standard quality to licensee.

3.2 The SLA shall be monitoring and ensuring the action taken by the licensee at all levels as per his instructions


3.3 The licensee is responsible for recall of product at all levels from supply chain and shall also be responsible according to the provisions for product recalls and also for the complaint and adverse reactions as envisaged in Para 27 and Para 28 of Schedule M and Rule 74(j) & 78 (i) of the Drugs & Cosmetics Rules.

3.4 For interstate co-ordination & communication, the zonal offices of CDSCO of their respective jurisdiction are responsible.



CENTRAL DRUGS STANDARD CONTROL ORGANIZATION, DGHS

Authorized Personnel Only

	TITLE		Division Name	Quality Assurance	
	Procedure for Recall and Rapid Alert System for Drugs including Biological & Vaccines		Document No.	QA-GNL-021	
			Revision No.	02	
			Effective Date	01.08.2015	
			Page No.	2 of 5	
Prepared By		Approved By		Authorized By	
Name		Name		Name	
Designation		Designation		Designation	
Sign		Sign		Sign	
Date		Date		Date	

4.0 ACCOUNTABILITY

SLA, Head Biological division, Zonal/Sub-zonal Heads & DCG (I)

5.0 PROCEDURE

5.1 As soon as the drug is declared as not of standard quality in Form 13- (Certificate of Test/Analysis) by Government Analyst and same is forwarded to the concerned Drugs Inspector by the laboratory. On the receipt of said report, the concerned inspector shall immediately intimate to their CA (when the manufacturer is not located in their state) & concerned LA (when manufacturer is located in their state).

5.2 The CA of that state under whose jurisdiction the sample is drawn shall inform to the concerned CA/SLA under whose jurisdiction manufacturer is located and also to the zonal offices of CDSCO for co-ordination.

5.3 The SLA under whose jurisdiction manufacturer is located shall direct the manufacturer to stop further sale or distribution and recall of batch of the product by means of sending the recall notice i.e. "Order to stop sale or distribution or use of drug & recall notice (Annexure-1) to the manufacturer (if located in his jurisdiction) and licensee shall recall such products (Annexure-2) as per the recall classification (Refer - Guidelines for Recall & Rapid Alert System) & record the details in Recall log.


5.4 The SLA shall communicate to stop the usage of the drug immediately in case of Class -I recall as per the Guidelines for Recall & Rapid Alert System through fastest mode of communication such as by mass media through newspapers, TV and in the departmental web portal. Most appropriate methods shall be used which may include issuance of notices, circulating letters to all SLAs by whichever possible mechanism so as to ensure that the fastest mode of transmission is used. It is preferred that informations are given by SMS or through website to the public and the regulatory mechanism shall try to reach that level.

5.5 The SLA/CA shall direct the area Drugs Inspector to freeze the stock in case of Class I recall for that batch if available for sale or distribution and the Drugs Inspector shall report action to SLA/CA the action taken within the stipulated time line.

CENTRAL DRUGS STANDARD CONTROL ORGANIZATION

CENTRAL DRUGS STANDARD CONTROL ORGANIZATION, DGHS

Authorized Personnel Only

	TITLE		Division Name	Quality Assurance	
	Procedure for Recall and Rapid Alert System for Drugs including Biological & Vaccines		Document No.	QA-GNL-021	
			Revision No.	02	
			Effective Date	01.08.2015	
			Page No.	3 of 5	
Prepared By		Approved By		Authorized By	
Name		Name		Name	
Designation		Designation		Designation	
Sign		Sign		Sign	
Date		Date		Date	

5.6 The Manufacturer shall be responsible for communication of recall at appropriate levels in the supply chain with the status on the stock in position and the progress of recall through Recall Notice to distributors /Marketing company /stockiest/retailers (Annexure-3) & summary report of recall (Annexure-4).

5.7 Recall status shall be intimated by the license manufacturer/wholesale/retail level to the area Drugs Inspector who shall be responsible for assessing the effectiveness of recall and shall intimate the same to the SLA.

5.8 The Manufacturer shall intimate to the concerned LA after completion of recall within the stipulated time line. The LA shall intimate the update to concern SLAs /CAs and CAs of respective CDSCO Zone/Sub-zone (in the matter where communications to interstate SLAs is required)


5.9 The SLA may initiate for investigation on not of standard quality drugs not only for the impugned batch but also if other batches could also be affected.

5.10 After completion of investigation such products may be destroyed in presence of the area Drugs Inspector as instructed by SLA as per Bio Medical Waste Management & Handling Rules, 1998and records shall be maintained.

6.0 ANNEXURE / FORMAT

Annexure/Format No.	Title
Annexure-1	Specimen format of order to stop sale or distribution or use of drug & recall notice.
Annexure-2	Specimen format of Recall log.
Annexure-3	Specimen format of Recall notice to distributors / marketing company /stockists/ retailers.
Annexure-4	Specimen format of SummaryReport ofRecall

Format No. QA-GNL-001/F01-01

	TITLE		Division Name	Quality Assurance	
	Procedure for Recall and Rapid Alert System for Drugs including Biological & Vaccines		Document No.	QA-GNL-021	
			Revision No.	02	
			Effective Date	01.08.2015	
			Page No.	4 of 5	
Prepared By		Approved By		Authorized By	
Name		Name		Name	
Designation		Designation		Designation	
Sign		Sign		Sign	
Date		Date		Date	

7.0 REFERENCES

Doc. No.	Title
1	Drugs & Cosmetics Act 1940 & Rules 1945.
2	Good Distribution Practices by WHO.
3	Good Manufacturing Practices by WHO.
4	The Guidelines on Recall & Rapid Alert System for Drugs including Biologicals and Vaccines
5	The Bio Medical Management & Handling Rules, 1998.
6	43 rd DCC sub-committee Guidelines

8.0 ABBREVIATION

Acronym	Full Form
SOP	Standard Operating Procedure
QA	Quality Assurance
SLA	State licensing Authority
CLAA	Central Licensing Approval Authority
LA	Licensing Authority
CA	Controlling Authority
CDSCO	Central Drugs standard control organization
NSQ	Not of Standard Quality
WH	Warehouse


9.0 REVISION HISTORY

Revision No.	Reason(s) for Revision
00	New SOP
01	Implementation of New Format
02	- Implementation of New Format and periodic

CENTRAL DRUGS STANDARD CONTROL ORGANIZATION

CENTRAL DRUGS STANDARD CONTROL ORGANIZATION, DGHS

Authorized Personnel Only

	TITLE		Division Name	Quality Assurance	
	Procedure for Recall and Rapid Alert System for Drugs including Biological & Vaccines		Document No.	QA-GNL-021	
			Revision No.	02	
			Effective Date	01.08.2015	
			Page No.	5 of 5	
Prepared By		Approved By		Authorized By	
Name	Name		Name		
Designation	Designation		Designation		
Sign	Sign		Sign		
Date	Date		Date		

	revision -Point 5.4 revised to include SMS and use of website for mode of communication
--	--



Annexure-1 of QA-GNL-021

'CLAA-Specimen Letter for Recall of Not of Standard Quality Batch of Vaccine'

Central Drugs Standard Control Organization

Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India FDA Bhavan, ITO, Kotla Road, New Delhi -110002

ORDER TO STOP SALE OR DISTRIBUTION OR USE OF DRUG & RECALL NOTICE

FILE NO.:

TO,

DATE:

< Name and Address of the Licensee >

This is to intimate you that < Name of the Product-----, Batch No. -----, Date of Manufacture-----, Date of Expiry-----, Manufactured By M/s (Name of the Manufacturer and address-----) > has been declared by < Name of the Laboratory----- > as not of standard quality; vide < Letter/Report Number dated > for the reasons that < reasons to

declare the product as NSQ-----> declared as NSQ whose copy is enclosed for your reference. The above drug has reported to be causing serious adverse events /death.

You are, therefore, directed to stop distribution, sale or use of above mentioned drug and to initiate its recall from the market. Also you are directed to submit details within ----- hours/days as per recall class -----to this office as per the enclosed formats.

(Signature, Name and Address of CA/SLA)

Copy for information and necessary action to:

1. The State Licensing Authority of all the States/UTs of Union of India for action to stop distribution, sale or use of above mentioned drug in their jurisdiction.
2. The Zonal or Sub-Zonal Office of concerned CDSCO.



Annexure-2 of QA-GNL-021
 'Recall Log'

Central Drugs Standard Control Organization

Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India
 FDA Bhavan, ITO, Kotla Road, New Delhi -110002

RECALL LOG

(To be filled in by licensee / representative of licensee)

Recall ref. no.	Time & Date of recall Initiation	Product name	Batch / Lot No	Mfg Date	Exp Date	Reason for recall	Classification [Class I,II,III]	Quantity Produced / B. Size (A)	Unsold or Undistributed quantity in possession (B)	Quantity Distributed (C)	Quantity Returned / Recalled	Closure Date & Sign.	Remarks



Annexure-4 of QA-GNL-021

‘Summary Report of Recall’

Central Drugs Standard Control Organization

Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India FDA Bhavan, ITO, Kotla Road, New Delhi -110002

SUMMARY REPORT OF RECALL


Part A: To be filled by Distributor / Retailer as applicable

Recall Ref. No.		Date:		
Product name				
Batch no.		Mfg Date:		
Reason for Recall				
Name of Customer	Qty. Received on purchase invoice (A)	Quantity Sold (B)	Quantity Un distributed / Stock in Hand (C)=(A)-(B)	Quantity Received from Customer in response to recall (D)
Total Quantity	(G)=	(H)	(E)	(F)
Stock not distributed (E)				
Quantity available in Warehouse after Recall (E+F)				
Total quantity received with purchase invoice (Purchase Invoice No., Date, etc.)(G)				
Justification for any Deviations observed During reconciliation				
Stock / Sale License No.				
Prepared by: Retailer / Wholesaler (Personnel Sign/Date)				

Part B: To be filled by manufacturer

Batch Disposition:	Quantity:..... to be;	Batch Size:		
	Destroyed Reprocessed	Reworked	Any other (specify)	

<p>Recall Summary: (Also mention, action taken if product was still available for sale or use)</p> <p style="text-align: right;">Licensee / Representative of licensee</p>





CENTRAL DRUGS STANDARD CONTROL ORGANISATION

Directorate General of Health Services
Ministry of Health and Family Welfare, Government of India
FDA Bhawan, Kotla Road, New Delhi -110002